Baird Maintains Outperform on Leap Therapeutics, Lowers Price Target to $9
Portfolio Pulse from Benzinga Newsdesk
Baird analyst Joel Beatty has maintained an Outperform rating on Leap Therapeutics (NASDAQ:LPTX) but has lowered the price target from $11 to $9.

March 19, 2024 | 11:09 am
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Baird analyst Joel Beatty maintains an Outperform rating on Leap Therapeutics but lowers the price target from $11 to $9.
While the reduction in price target could suggest a tempered outlook on the stock's potential upside, the maintenance of an Outperform rating indicates continued confidence in the company's fundamentals and growth prospects. This mixed signal could lead to neutral short-term price movement as investors weigh the implications.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100